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In vitro anthracycline cross-resistance pattern in childhood acute
lymphoblastic leukaemia
E Klumper, R Pieters, ML den Boer, DR Huismans, AH Loonen and AJP Veerman
Department ofPaediatrics, Free University Hospital. PO Box 7057, 1007 MB Amsterdarn The Netherlands.
Summary Daunorubicin (DNR) is a major front-line drug in the treatment of childhood acute lymphoblastic
leukaemia (ALL). Previously, we showed that in vitro resistance to DNR at diagnosis is related to a poor
long-term clinical outcome in childhood ALL and that relapsed ALL samples are more resistant to DNR than
untreated ALL samples. In cell line studies. idarubicin (IDR). aclarubicin (ACR) and mitoxantrone (MIT)
showed a (partial) lack of cross-resistance to the conventional anthracyclines DNR and doxorubicin (DOX).
but clinical studies in childhood ALL have been inconclusive about the suggested lack of cross-resistance. In
the present study we determined the in vitro cross-resistance pattern between DNR. DOX. IDR. ACR and
MIT in 48 untreated and 39 relapsed samples from children with ALL using the MTT assay. The relapsed
ALL group was about twice as resistant to DNR. DOX. IDR. ACR and MIT as the untreated ALL group.
Thus, resistance developed to all five drugs. We found a significant cross-resistance between DNR. DOX.
IDR. ACR and MIT. although in some individual cases in vitro anthracycline cross-resistance was less
pronounced. We conclude that IDR. ACR and MIT cannot circumvent in vitro resistance to DNR in
childhood ALL. Clinical studies may still prove whether IDR. ACR or MIT has a more favourable toxicity
profile than DNR.
Keywords: MTT assay: chemosensitivityv drug resistance: daunorubicin; doxorubicin; idarubicin: aclarubicin:
mitoxantrone; leukaemia
Two-thirds of children with newly diagnosed acute lymphob-
lastic leukaemia (ALL) can now be cured with combination
chemotherapy, but chemotherapy fails in the remaining third,
mainly because the leukaemia relapses (Niemeyer et al..
1991). Despite intensive salvage chemotherapy. children with
relapsed ALL still have a poor prognosis, and only one-third
of them can be cured (Henze et al., 1991). Anthracychnes,
such as daunorubicin (DNR) and doxorubicin (DOX). are
commonly used in combination with several other classes of
drugs in the treatment of childhood ALL. However, their
clinical use is limited by cardiotoxicity and the development
of drug resistance (Weiss, 1992). Previously, we showed that
samples from children with relapsed ALL are more resistant
to DNR than samples from children with untreated ALL
(Pieters et al.. 1992: Klumper et al.. 1993).
Anthracycline analogues lacking cross-resistance may cir-
cumvent resistance to DNR or DOX and may improve
chemotherapy for relapsed childhood ALL. Many analogues
have been developed since DNR and DOX were discovered
in the early 1960s, but only a few have reached clinical trials
(Muggia and Green, 1991). Idarubicin (IDR), aclarubicin
(ACR) and the structurally closely related mitoxantrone
(MIT) show a (partial) lack of cross-resistance to DNR and
DOX in different cell lines (Hill et al.. 1985; Coley et al..
1989; Erttmann et al.. 1991). Clinical studies with anthracyc-
line analogues in childhood ALL are inconclusive about the
suggested lack of cross-resistance. since no randomised com-
parative studies have been reported to date. In the present
study, we determined the in vitro cross-resistance pattern
between DNR. DOX. IDR, ACR and MIT within an
uniform group of fresh samples obtained from 48 children
with untreated ALL and 39 children with relapsed ALL.
Materials and methods
Drugs
We tested the following drugs: DNR (Polyfarma, The
Netherlands), DOX and IDR (Montedison. The Nether-
Correspondence: E Klumper
Received 5 October 1994: revised 1 Februars 1995; accepted 2 Feb-
ruarv 1995
lands), MIT (Lederle. The Netherlands). ACR was a
generous gift from Lundbeck (Copenhagen. Denmark).
DNR, DOX and IDR were dissolved in distilled water. ACR
was dissolved in ethanol. MIT was obtained in soluble form.
All drugs were further diluted with RPMI-1640 (Dutch
modification. Gibco, Uxbridge. UK) and stored at - 20'C in
stock solutions of 50gml-1' (MIT). l00 gml-' (DNR,
IDR) and 400 g ml-l (DOX. ACR). Microculture plates
were prepared with serial 4-fold drug dilutions derived from
these stock solutions, and the plates were stored at -20°C to
facilitate large-scale testing. We used in vitro concentration
ranges that covered clinical plasma concentrations (Table I).
Anthracycines can be safely stored at - 20'C up to 9 months
without decomposition (Scott et al.. 1986). and without loss
of in vitro anti-leukaemic efficacy of all drugs tested (data not
shown).
Leukaemic samples
Bone marrow (BM) and or peripheral blood (PB) samples
were obtained, with informed consent, from 48 children with
newly diagnosed ALL and 39 children with relapsed ALL.
All children from the relapsed ALL group had previously
been exposed to DNR and or DOX as part of multidrug
front-line chemotherapy. None of the children with relapsed
ALL had been tested before at initial diagnosis. Samples
were processed within 24 h after collection.
Mononuclear cells were isolated by Ficoll density-gradient
centrifugation (Ficoll Paque, density 1.077g ml-'; Pharmacia,
Sweden) and washed twice in RPMI-1640 containing 0.1%
bovine serum albumin. Representative in vitro drug resistance
data can be generated if more than 70% ALL cells are
present after a 4 day cell culture. since in vitro drug resistance
will be overestimated if more than 30% contaminating non-
malignant cells are present (Kaspers et al.. 1994). To increase
the number of evaluable cell cultures, the leukaemic cell
population was enriched in 10 87 samples by removing con-
tamiinating non-malignant cells using monoclonal antibodies
linked to magnetic beads (Dynabeads M450. Dynal. Nor-
way). We incubated cell suspensions (50 x 106 cells ml-') for
30 mmn at 37'C with one or a combination of the following
mouse monoclonal antibodies (ITK, The Netherlands)
directed against myeloid cells (CD13 and CD15, dilution 1:50A rdine acoss-esistance in Iukaenia
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Table I In vitro and in vivo drug concentrations
In vitro In vivo
Concentration PPCU in jig ml- I
Drugs range in igml-' (dose mg m-- i.V.) References
DNR 0.002 - 2.0 0.23 (45) Speth et al. (1989)
DOX 0.008 - 8.0 1.64 (30) Speth et al. (1987)
IDR 0.002 - 2.0 0.05 (10) Speth et al. (1989)
ACR 0.002 - 2.0 0.03 (25) Yamada et al. (1980)
MIT 0.001 - 1.0 0.68 (15) Van Belle et al. (1986)
APPC. peak plasma concentration after one i.v. bolus.
Table II In vitro antileukaemic activity and in vivo toxicitV
In vitro In vivo
Relative Relative
Drugs LCwa activiti MUTD' toXiciti4 References
IDR 0.025 1.0 15 - 18 1.0 Ganzina etal. (1986)
MIT 0.049 2.0 24 - 33 1.3 - 2.2 Ungerleider et al. (1985)
DNR 0.083 3.3 60 - 75 3.3 - 5.0 Carter and Livingston (1982)
ACR 0.118 4.7 85 - 120 4.7 - 8.0 Van Echo et al. (1982)
DOX 0.255 10.2 60 - 75 3.3 - 5.0 Carter and Livingston (1982)
AMedian LC< in ig ml- 'ofthe untreated ALL group. bLC50 ofeach drug relative to IDR. cMaximum
tolerable dose in mg m- after one i.v. bolus. dMTD of each drug relative to IDR.
or 1:100). monocytes (CD14. dilution 1:100) or
T lymphocytes in case of non-T-lineage ALL samples (CD2.
dilution 1:100). Cell suspensions were washed three times
with RPMI and 10% fetal calf serum. Magnetic beads.
coated with sheep anti-mouse immunoglobulin G. were
added to the cell-antibody suspension (ten beads to one
target cell) for 30 min at 37°C. The contaminating normal
cells. linked through antibodies to the beads, were separated
from the leukaemic cells by magnetic force. The mean
percentage of leukaemic cells of the ten samples treated with
beads increased from 75% to 89% using this method. The in
vitro chemosensitivity of leukaemic cells was not influenced
by treatment with monoclonal antibodies linked to beads
(Kaspers et al.. 1994).
In vitro chemosensitivitv
In vitro chemosensitivity did not differ between BM and PB
samples (Kaspers et al.. 1991). All samples were freshly
cultured with the exception of one cryopreserved sample. The
MIT assay was performed as described before (Pieters et al..
1990). Briefly, microculture plates containing 96 wells with
20 ji1 frozen aliquots of a drug were thawed just before
testing and 80 Li of leukaemic cell suspension (2 x 106m1')
was added. Leukaemic cells were cultured for 4 days in the
absence or presence of six concentrations of each drug in
duplicate.
May-Gru5nwald Giemsa-counterstained cytospins of cont-
rol cells were made and showed that all samples contained
) 80% leukaemic cells at onset of the cell culture and
) 70% leukaemic cells after a 4 day cell culture. After 4
days. we added 10 jii of 5 mg ml-' MIT to each well and the
microculture plates were incubated for another 6 h. The tet-
razolium salt MTT is reduced to dark-coloured formazan
crystals by viable cells only. Formazan crystals were dis-
solved with 100 pi of acidified isopropanol. The optical den-
sity (OD) was measured at 565 nm with an EL-312 microp-
late reader (Biotek Instruments. Winooski, USA). The OD is
linearly related to the number of viable cells (Kaspers et al.,
1991). We calculated the leukaemic cell survival (LCS) from
the following equation:
ODtted cEls
LCS= x 100%
mean ODc13ono s
We used the LC«. the drug concentration lethal to 50% of
the leukaemic cells. as parameter of in vitro chemosensitivity.
Comparable in vitro drug resistance data can be obtained by
repeated testing of samples. LCio values fall within the range
of one dilution step (data not shown).
Statistics
The LC,0 values were non-parametrically distributed.
Therefore, differences in the LC* distribution between unt-
reated and relapsed childhood ALL samples were tested
using the two-tailed Mann-Whitney L'-test. Spearman rank
correlation coefficients (rho) were calculated to determine the
cross-resistance patterns between the drugs tested.
Results
Anti-leukaemic activitY
In general. for each drug steep dose-response curves were
obtained. In vitro chemosensitivity was not influenced by cell
culture efficiency: we found no significant correlations
between the LC,0 values of each drug and the control
leukaemic cell survival (rho = -0.01 to 0.06. P>0.50) or
between the LC,0 values and the OD per 10' viable control
cells (rho =-0.01 to 0.19, P> 0.08). The in vitro chemosen-
sitivity varied 40- to 300fold among all patients: LC_% values
(jag ml-') of DNR ranged from 0.012 to 1.294, of DOX from
0.023 to 1.374. of MIT from 0.003 to > 1. of IDR from
0.002 to 0.363 and of ACR from 0.037 to 1.531.
IDR was in vitro the most active anti-leukaemic drug.
Intra-patient comparisons showed that in general the lowest
LCO values were found for IDR. followed by MIT, DNR.
ACR and DOX. In Table II the median LC_% values of the
untreated ALL samples are ranked and the anti-leukaemic
activity is given relative to IDR; for example. a 3.3-fold
higher DNR concentration is required compared with IDR
to obtain an equal in vitro anti-leukaemic response. However.
Table I1 shows that an increase in in vitro anti-leukaemic
activity corresponds to an increase in the clinical toxicity as
defined by the maximum tolerable dose (MTD) after one
intravenous bolus of each drug; for example compared with
DNR. IDR is in vitro about 3-fold more active, but the
equitoxic dose of IDR is about 3-fold lower.
U-ntreated vs relapsed childhood ALL
The control leukaemic cell survival did not differ (P = 0.66)
between untreated (median 75%. range 35-138%) and
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relapsed (median 72%. range 27-259%) childhood ALL
samples. The OD per I03 control leukaemic cells did not
differ (P=0.20) between untreated (median 0.235, range
0.082-0.649) and relapsed (median 0.257, range 0.108-0.675)
childhood ALL samples. Despite considerable overlap of the
LC50 values between both groups, the relapsed ALL group
was significantly more resistant (0.001 <P <0.033) to all
five drugs tested than the untreated ALL group (Figure 1).
We calculated the resistance ratios, i.e. the ratio of the
median LC50 values from the relapsed and untreated
ALL group; the resistance ratios ranged from 1.5 to 2.7
(Table III).
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Cross-resistance pattern
We found a significant (P<0.001) correlation between the
LC50 values of all drugs tested in 87 childhood ALL samples
(Table IV). Figure 2 shows the cross-resistance pattern in
childhood ALL between the front-line drug DNR vs DOX,
IDR, ACR and MIT. Separate analyses of the untreated
(n = 48) and relapsed (n = 39) ALL groups gave comparable
Spearman rank correlation coefficients. A strong correlation
was found between DNR, DOX, IDR and MIT
(rho = 0.75-0.84), and to a lesser extent between ACR and
the other four drugs (rho = 0.50-0.57).
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Figre 1 The in vitro cytotoxicity of daunorubicin, doxorubicin, idarubicin, aclarubicin and mitoxantrone in 48 untreated
compared with 39 relapsed samples from children with acute lymphoblastic leukaemia. Note that different scales for the y-axis are
used. Median LC50 values are indicated ( ).
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1We have shown previously that resistance to DNR at initial
diagnosis is correlated with a poorer long-term clinical out-
come in childhood ALL (Pieters et al., 1991). Moreover,
resistance to DNR and several other drugs such as pred-
nisolone and L-asparaginase. might explain the poor prog-
nosis of relapsed childhood ALL (Klumper et al.. 1993).
Analogues lacking cross-resistance to DNR can theoretically
circumvent DNR resistance, which may improve chemo-
therapy in relapsed childhood ALL. These analogues, such as
IDR. ACR and MIT, have been identified in several cell line
studies (Hill et al.. 1985; Coley et al., 1989; Erttmann et al.,
1991). However, other cell line studies have reported contras-
ting in vitro resistance patterns, for example a full cross-
Table III Comparison of the in vitro chemosensitiVity between 48
untreated and 39 relapsed children with ALL
Median LCsfa in 1tg ml-I
Resistance
Drugs CUntreated Relapsed ratioh P-value'
DNR 0.083 0.121 1.5 <0.001
DOX 0.255 0.390 1.5 <0.001
IDR 0.025 0.068 2.7 <0.001
ACR 0.118 0.244 2.1 0.005
MIT 0.049 0.078 1.6 0.033
aLC0O drug concentration lethal to 50% ofthe ALL cells. bResistance
ratio, the ratio of the median LC50 values from the relapsed and
untreated ALL group. 'Two-tailed Mann-Whitney U-test.
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resistance between MIT vs DNR and DOX has been found
(Scott et al., 1986: Gupta et al.. 1988). There is a need for
such comparative studies using patient samples.
In the present study, we showed that samples from child-
ren with relapsed ALL were 2-fold more resistant not only to
DNR and DOX. but also to IDR, ACR and MIT. compared
with the untreated childhood ALL group. Moreover, the in
vitro cytotoxicities of DNR. DOX, IDR. ACR and MIT
were closely correlated. Thus, a pronounced cross-resistance
developed to all five drugs suggesting that IDR. ACR and
MIT cannot circumvent DNR resistance in childhood ALL.
However, our results do not exclude the possibility that some
individual children with relapsed ALL might benefit from
ACR after front-line therapy including DNR, since we found
a less pronounced although still significant cross-resistance
between ACR and the other drugs tested.
Although relapsed ALL samples were more resistant than
untreated ALL samples to all five drugs tested, the LC^O
Table IV Spearman correlation coefficients! ofdaunorubicin (DNR).
doxorubicin (DOX). idarubicin (IDR). mitoxantrone (MIT) and
aclarubicin (ACR) in 87 childhood ALL samples
DNR DOX IDR MIT ACR
DNR - 0.84 0.84 0.75 0.53
DOX 0.84 - 0.82 0.81 0.57
IDR 0.84 0.82 - 0.81 0.51
MIT 0.75 0.81 0.81 - 0.50
ACR 0.53 0.57 0.51 0.50 -
aAll correlations were significant at P<0.001.
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Figure 2 The in vitro cross-resistance pattern of daunorubicin vs doxorubicin. idarubicin. aclarubicin and mitoxantrone in 87
samples from children with acute lymphoblastic leukaemia. Each point represents a paired LC, value (pg ml ')obtained from the
same patient sample.
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values of both groups showed considerable overlap. This
suggests that DNR resistance in relapsed ALL may already
be present at first diagnosis and that some children with
relapsed ALL remained chemosensitive to DNR. Cell lines
often express a 10- to more than 100-fold drug-induced
resistance, whereas we found relative low resistance ratios for
the anthracyclines in childhood relapsed ALL, ranging from
1.5 to 2.7. However, these resistance ratios were based upon
the ratio of the median LC_% of the relapsed compared with
the untreated ALL group; inter-patient chemosensitivities
differed over 100-fold. Although Hill et al. (1989) have
argued that cell lines expressing low levels of drug-induced
resistance would be more suitable for the study of clinically
relevant resistance mechanisms, our results based on patient
samples suggest that cell lines with both low and high levels
of drug-induced resistance could be used to investigate drug
resistance. These large inter-patient variations probably
reflect the clinical heterogeneity of tumour samples, which
hampers the extrapolation of results from single cell line
studies to clinically relevant results.
No anthracycine resistance mechanisms or strategies to
modulate anthracycine resistance with major clinical
relevance in childhood ALL have been identified so far.
P-glycoprotein expression has been most extensively studied
in childhood ALL. but most studies could not detect
significant differences in P-glycoprotein expression between
untreated and relapsed childhood ALL samples (Ubezio et
al., 1989: Tawa et al.. 1990: Mizuno et al., 1991; Gekeler et
al.. 1992: Pieters et al.. 1992: Brophy et al., 1994), whereas
the latter samples were significantly more resistant to
anthracycines in the present study. Moreover, we showed
previously that neither verapamil nor cyclosporin A could
modulate in vitro DNR resistance in childhood ALL (Pieters
et al., 1992). Although multiple factors are likely to cause
drug resistance, short-term cell culture drug resistance assays,
such as the MTT assay, measure the end point of all possible
resistance mechanisms, i.e. leukaemic cell kill, which is shown
to be of predictive value in childhood ALL (Pieters et al.,
1991).
Our results suggest that IDR, ACR and MIT do not have
a higher therapeutic index than DNR since their in vitro
anti-leukaemic activity was paralleled by their toxicity on
normal cells, represented by the MTD. We found that IDR
was the most active anti-leukaemic drug in vitro, a fact that is
well known (Fields and Koeller, 1991). One clinical study
reported a higher (statistically not significant) complete
remission rate with IDR (75%) than DNR (59%) when both
are used in combination chemotherapy in relapsed childhood
ALL (Feig et al.. 1992). However, this study used increasing
IDR doses to determine its MTD in combination
chemotherapy, while the dose intensity of DNR was given
below the MTD level. as shown by a significant higher
toxicity in the group of children treated with IDR. Although
our study suggests that the therapeutic index may not differ
between IDR and DNR. we did not take into account other
advantages of IDR compared with DNR, such as oral
administration (Erttmann et al.. 1988; Pui et al.. 1988) and
penetration of the cerebrospinal fluid (Reid et al.. 1990). In
contrast to childhood ALL. a large randomised study in
adult acute myeloid leukaemia (AML) reported a superior
response rate for IDR compared with DNR in remission
induction chemotherapy (Berman et al.. 1991).
Although our results suggest that IDR. ACR and MIT
cannot circumvent DNR resistance in childhood ALL.
clinical studies with IDR. ACR and MIT showed marked
anti-leukaemic responses in children with relapsed ALL
previously treated with DNR or DOX (Vietti et al.. 1983:
Starling et al.. 1985: Ungerleider et al.. 1985: Fengler et al..
1987; Madon et al.. 1987: Tan et al.. 1987: Erttmann et al..
1988; Pui et al.. 1988; Giona et al.. 1990: Graham et al.,
1991). However, the response rate for DNR and DOX in
such selected patient groups is not known and might well be
similar to that of the other three drugs mentioned. Moreover.
a second complete remission rate up to 90% can be achieved
with combination chemotherapy in relapsed childhood ALL
(Henze et al.. 1991). Thus, a response to IDR. ACR or MIT
in relapsed childhood ALL is not conclusive for a lack of
cross-resistance to DNR and or DOX. Phase I II single-agent
studies are difficult to compare as small. highly selective
patient groups are usually tested, in contrast to our study
comparing five drugs within a uniform patient group.
In summary, we showed that the relapsed ALL group was
about twice as resistant to DNR, DOX, IDR. ACR and MIT
as the untreated ALL group. Significant cross-resistance was
observed between DNR, DOX. IDR, ACR and MIT,
indicating that IDR, ACR and MIT cannot circumvent in
vitro resistance to the conventional compounds DNR and
DOX in childhood ALL samples. These results suggest that
IDR, ACR and MIT are unlikely to enhance the anti-
leukaemic response by replacing DNR in combination
chemotherapy of relapsed childhood ALL, but these results,
based upon cellular drug resistance proffles, do not exclude
possible pharmacokinetic advantages of these analogues.
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